Table 2.

Covariate-adjusted Cox analyses of the association between cardiac troponin T levels by a highly sensitive assay (hs-cTnT) and incident atrial fibrillation (AF) in the Cardiovascular Health Study (CHS)

	Model 1 HR (95%CI)	Model 2 HR (95%CI)	Model 3 HR (95%CI)	Model 4 HR (95%CI)
Log-transformed hs-cTnT values
Spline model, knot at log (hs-cTnT) = 3.25
Spline 1*, hs-cTnT ≤24.53	1.67 (1.52,1.83)	1.45 (1.32,1.59)	1.39 (1.26,1.53)	1.21 (1.10,1.34)
Spline 2*, hs-cTnT >24.53	0.97 (0.67,1.39)	0.88 (0.60,1.29)	0.79 (0.52,1.18)	0.66 (0.44,1.00)
hs-cTnT levels (ng/L)
<3.00 (undetectable)	1 (reference)	1 (reference)	1 (reference)	1 (reference)
3.00–6.23 (1st tertile)	1.16 (0.99,1.36)	1.09 (0.93,1.28)	1.08 (0.93,1.27)	1.02 (0.88,1.20)
6.24–10.97 (2nd tertile)	1.50 (1.29,1.75)	1.32 (1.13,1.54)	1.27 (1.09,1.49)	1.12 (0.96,1.32)
>10.97 (3rd tertile)	2.39 (2.03,2.82)	1.89 (1.60,2.24)	1.75 (1.48,2.08)	1.38 (1.16,1.65)

Model 1 adjusted for age, race, and gender.

Model 2 additionally adjusted for body mass index, known prevalent coronary disease or myocardial infarction, prevalent heart failure, smoking status (current vs not), systolic blood pressure, fasting glucose levels, and use of antihypertensive (beta-blocker, calcium channel blocker, diuretic, vasodilator, angiotensin-converting enzyme inhibitor, angiotensin type 2 antagonist), antiarrhythmic (any class IA, IB, IC or III agents), or digoxin.

Model 3 adjusted for model 2 variables and incident heart failure.

Model 4 adjusted for model 2 variables and baseline levels of N-terminal pro–B-type natriuretic peptide and C-reactive protein (both log transformed).

CI = confidence interval.

^*Hazard ratio (HR) per log(hs-cTnT) increase.